title: Chemotherapy in soft tissue sarcoma. The Scandinavian Sarcoma Group experience.
abstract: The first chemotherapy study of soft tissue sarcoma (STS) by the Scandinavian Sarcoma Group was started in 1981 (SSG I). It evaluated the single agent adjuvant doxorubicin in a randomized setting in patients with high-grade STS. No improvement was noted in the overall survival or disease-free survival rate. More intense chemotherapy was thereafter (1991-1994) evaluated in a phase 2 study, introducing ifosfamide and a continuous infusion of etoposide with growth factor (SSG X). The response rate of previously untreated patients was high (42%), but complete remissions were few. Analysis of patients undergoing surgery after preoperative chemotherapy suggested an increased survival. A recent meta-analysis of adjuvant chemotherapy for localized resectable STS in adults, including the SSG I trial, indicated a better disease-free survival and possibly improved overall survival (Thierny et al. 1997). At present, we are studying whether such a benefit can be shown in patients with high-risk prognostic criteria by giving adjuvant ifosfamide and doxorubicin treatment after primary surgery (SSG XIII). In the latter SSG study, started on July 1, 1998, the adjuvant therapy is evaluated in a phase 2 study in selected patients with high-grade STS and other unfavorable prognostic factors.
authors.affiliation: Dept. of Oncology, Karolinska Hospital, Stockholm, Sweden.
authors.forename: J O
authors.initials: JO
authors.lastname: Fernberg
authors.forename: T
authors.initials: T
authors.lastname: Wiklund
authors.forename: O
authors.initials: O
authors.lastname: Monge
authors.forename: K S
authors.initials: KS
authors.lastname: Hall
authors.forename: G
authors.initials: G
authors.lastname: Saeter
authors.forename: T A
authors.initials: TA
authors.lastname: Alvegård
authors.forename: H
authors.initials: H
authors.lastname: Strander
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use*; D005047:Etoposide / Q000627:therapeutic use*; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use*; D011379:Prognosis; D012042:Registries; D012074:Remission Induction; D012307:Risk Factors; D012509:Sarcoma / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D012537:Scandinavian and Nordic Countries; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide; D004317:Doxorubicin; D007069:Ifosfamide